Guardant Health Inc. (GH) shares surged 5.28% in pre-market trading, driven by a wave of positive analyst actions that included multiple price target increases from major financial firms.

The significant pre-market gain follows reports that several analyst firms have raised their price targets for Guardant Health. Stifel increased its target to $130 from $120, Leerink Partners raised to $180 from $170, Canaccord boosted to $135 from $125, JPMorgan and Barclays both raised to $130 from $120, BTIG increased to $145 from $140, and TD Cowen raised to $135 from $130.

These analyst actions reflect growing optimism about Guardant Health's prospects, with the company recently reporting quarterly revenue growth of 39.4% to $281.27 million, surpassing analyst expectations. The bullish sentiment is further supported by the current average analyst rating of "buy" with 23 "strong buy" or "buy" recommendations out of 26 total analyst ratings.